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Abstract
Introduction The Japan Renal Biopsy Registry (J-RBR)
was started in 2007 by the Committee for the Standard-
ization of Renal Pathological Diagnosis and the Committee
for the Kidney Disease Registry of the Japanese Society of
Nephrology. The purpose of this report is to clarify drug-
induced kidney disease (DIKD) of renal biopsied cases in
Japan.
Subjects and methods We analyzed the data of 26,535
cases that were registered in the J-RBR from 2007 to 2015.
Results Based on clinical and pathological diagnoses, 328
cases (176 males and 152 females) of renal biopsy-proven
DIKD were registered in the J-RBR from 2007 to 2015
(1.24 % of all cases). The frequency of DIKD increased
with age. The number of cases peaked in the 6th–8th
decade in all pathological categories, except for the number
of chronic tubulointerstitial lesions (CTIL), which peaked
in the 4th–5th decade. Overall, the frequency of DIKD was
3 times higher in the 7th decade than in the 2nd decade
(1.86 vs. 0.62 %). The main clinical diagnoses were DIKD
in 150 cases (45.7 %), nephrotic syndrome in 66 cases
(20.1 %), chronic nephritic syndrome in 55 cases (16.8 %),
and rapidly progressive glomerulonephritis in 30 cases
(9.1 %). DIKD was registered as a secondary diagnosis in
136 cases (41.5 %). The pathological findings of these
cases were glomerular lesions in 105 cases (32.0 %), acute
tubulointerstitial lesions (ATIL) in 87 cases (26.5 %),
CTIL in 72 cases (22.0 %), and sclerotic glomerular
lesions and/or nephrosclerosis in 18 cases (5.5 %). ATIL
and CTIL were mainly found in cases in which DIKD was
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diagnosed on the basis of the patient’s clinical findings. In
addition, nephrotic syndrome-related membranous
nephropathy (MN) was the major cause of renal damage in
59.4 % of the cases involving glomerular injuries.
According to the CGA risk classification, high-risk (red
zone) cases accounted for 56.1 % of all cases of DIKD and
75.9, 64.9, and 33.3 % of the cases involving ATIL, CTIL,
and glomerular injuries, respectively. The causative drugs
were identified in 102 cases, including bucillamine in 38
cases of MN, gemcitabine in 3 cases of thrombotic
microangiopathy, and other anticancer drugs in 14 cases
(anti-vascular endothelial growth factor drugs in 3 cases
and propyl thiouracil in 3 cases of anti-neutrophil cyto-
plasmic antibody-related nephritis).
Conclusion Our analysis of the J-RBR revealed that
DIKD mainly affects elderly people in Japan. ATIL or
CTIL were found in approximately half of the biopsied
cases of DIKD, and one-third involved glomerular lesions,
mainly MN or clinical nephrotic syndrome.
Keywords Drug  Kidney injury  Japanese  Nephrotic
syndrome  Tubulointerstitial nephritis
Introduction
The Japanese Society of Nephrology (JSN) established the
Japan Renal Biopsy Registry (J-RBR) in 2007, and in 2011
it conducted the first analysis of the registry, which
examined the data for 2007 and 2008 [1]. In 2009, the JSN
started the Japan Kidney Disease Registry (J-KDR) to
record clinically diagnosed cases of kidney disease. The
clinical training hospitals of the JSN were requested to add
data to this nationwide registry. Based on these data,
annual reports [1, 2], epidemiological and cross-sectional
studies of membranous nephropathy (MN) [3], elderly
patients with renal disease [4], diabetic nephropathy [5],
and renal disease combined with obesity [6], and a retro-
spective study of the outcomes of elderly patients with
nephrotic syndrome [7] have been reported, which have
helped to clarify the epidemiology of biopsied and
unbiopsied renal disease in Japan.
Drug-induced kidney disease (DIKD) accounts for
19–26 % of cases of acute kidney injury (AKI) among hos-
pitalized patients [8]. Recently, Mehta et al. have developed
consensus definitions for DIKD based on the patient’s clinical
presentation, which take into account the wide spectrum of the
condition and the need to balance practicality with reliability.
They proposed 4 phenotypes of DIKD: AKI, glomerular dis-
orders, tubular dysfunction, and nephrolithiasis [9]; however,
there are no biopsy-proven nationwide epidemiological data
about DIKD, even in Japan. Thus, we should develop methods
of identifying DIKD and produce preventive plans to protect
patients from developing the condition.
In this report, the data about renal biopsy-proven DIKD
that were registered in the J-RBR between July 2007 and June
2015 are summarized, and the frequency of the condition is
analyzed according to clinicopathological diagnosis and age.
Subjects and methods
Registry system and patients
This report includes data for the patients that were
prospectively registered in the J-RBR between July 2007
and June 2015. The patients’ data, including their age,
gender, laboratory findings, and clinical and pathological
diagnoses were recorded at each institution and registered
on the webpage of the J-RBR via the Internet Data and
Information Center for Medical Research (INDICE) system
of the University Hospital Medical Information Network
(UMIN), as described previously [1]. The ethics committee
of the JSN approved the study protocol, as did the local
committees of the participating centers and their affiliated
hospitals. Written informed consent was obtained from the
patients at the time of biopsy or at the time they were
registered to participate in the study. The J-RBR is regis-
tered in the UMIN Clinical Trials Registry (registered
number: UMIN000000618).
Clinical or renal histopathological diagnosis
and laboratory data
The clinical diagnosis, the histological diagnosis based on
the pathogenesis of the disease, and the histological diag-
nosis based on a histopathological examination were
recorded for each case included in the J-RBR, as described
previously [1]. Each diagnosis was based on the patients’
clinical symptoms and renal histopathology, as described
previously [10]. IgA nephropathy (Berger’s disease) was
differentiated from primary glomerular disease on the basis
of the glomerular alterations it causes, as described in the
classification of glomerular diseases produced by the
World Health Organization [10].
Clinical data, including urinalysis results and daily
proteinuria, serum creatinine (Cr), total protein, albumin,
and total cholesterol levels were recorded in all cases,
while recording data regarding systolic and diastolic blood
pressure, the use of anti-hypertensive agents, hemoglobin
A1c values, and the presence/absence of diabetes mellitus
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were considered to be optional. The estimated glomerular
filtration rate (eGFR) was calculated based on the patients’
serum Cr levels, as described previously [11].
Analyses of the frequency of DIKD according to age
and risk category (the heat map method)
We analyzed the frequency of DIKD according to age. In
addition, the frequency of high-risk (red zone) cases was
assessed in various arbitrary pathological categories, such
as glomerular lesions, acute tubulointerstitial lesions
(ATIL), chronic tubulointerstitial lesions (CTIL), and
sclerotic glomerular lesions and/or nephrosclerosis (scle-
rotic lesions), based on the CGA risk classification for
chronic kidney disease (the heat map method) [12].
Statistical analyses
Data are expressed as the mean ± SD for continuous
parametric data, the median and interquartile range for
continuous non-parametric data, and as frequencies for
categorical data.
Comparisons of categorical variables among groups of
different indications or diagnoses were performed using
Fisher’s exact test. Continuous variables were compared
using ANOVA for parametric data and the Kruskal–Wallis
test for non-parametric data. All statistical analyses were
performed using SPSS version 18.0 (SPSS, Tokyo, Japan).
Results
Baseline characteristics of the patients included
in the J-RBR and the DIKD patients
Among the cases included in the registry from July 2007 to
June 2015, the numbers of cases in which renal biopsies
were and were not performed are shown in Fig. 1. From
this cohort, 328 cases (176 males and 152 females) of renal
biopsy-proven DIKD were extracted based on their clinical
and/or pathological diagnoses (1.24 % of the 26,535 cases
registered in the J-RBR from 2007 to 2015).
There was no significant difference in the frequency of
DIKD between the first period (July 2007–June 2012) and
the second period (July 2012–June 2015) (220 cases out of
17,297 cases, 1.27 % vs. 108 cases out of 9238 cases,
1.17 %; not significant).
The frequency of clinical and pathological diagnoses
in DIKD
The main clinical diagnoses were DIKD in 150 cases
(45.7 %), nephrotic syndrome in 66 cases (20.1 %), chronic
nephritic syndrome in 55 cases (16.8 %), and rapidly pro-
gressive nephritic syndrome in 30 cases (9.1 %). DIKD was
registered as a secondary diagnosis in 136 cases (41.5 %);
thus, 286 cases (87.2 %) were diagnosed as DIKD based on
their clinical symptoms (Table 1). Another 36 cases (12.8 %)
were diagnosed as DIKD based on their pathological findings.
The pathological findings of these cases included
glomerular lesions in 105 cases (32.0 %), ATIL in 87 cases
(26.5 %), CTIL in 72 cases (22.0 %), and sclerotic
glomerular lesions and/or nephrosclerosis in 18 cases
(5.5 %) (Table 2, Supplemental Table 1). ATIL and CTIL
were most commonly associated with a clinical diagnosis
of DIKD. In addition, nephrotic syndrome-related MN was
the major cause of glomerular lesions in 59.4 % of the
cases involving glomerular lesions (Table 2).
The frequencies of the 3 major pathological categories
did not differ significantly between the first (July 2007–
June 2012) and second periods (July 2012–June 2015)
(Supplemental Table 1).
The numbers of cases and frequency of DIKD
according to age and pathological category
The total number of cases of DIKD is shown in Fig. 2 and
Supplemental Table 2, and the frequency of DIKD
increased with age until the 7th decade (Fig. 2a). The
number of cases of DIKD peaked in the 6th–8th decade in
All cases on J-RBR/J-KDR/CKD/DM n = 29,495
Selected cases for analysis
Drug related clinical diagnosis n = 328
2007-2012 n = 220
2013-2015 n = 108
Male : Female 176 : 152
Selected cases (J-RBR) n = 26,535
Cases excluded from analysis n = 2,960
J-KDR n=2,056
DM n=432
CRF/CKD n=471
AKI n= 1
Baseline characteriscs of the J-RBR and DIKD patpopulation ients
Fig. 1 Baseline characteristics of the J-RBR population and the drug-
induced kidney disease patients. From among the 26,535 cases that
were registered in the J-RBR between 2007 and 2015, 328 cases (176
males and 152 females) of renal biopsy-proven DIKD were extracted
based on their clinical and/or pathological diagnoses
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both genders, and in males a particularly marked peak was
seen in the 7th decade (Fig. 2b).
As for the frequency of DIKD among the renal biopsied
cases in each decade, the frequency of DIKD was 3 times
higher in the 7th decade than in the 2nd decade (1.86 vs.
0.62 %) (Fig. 3, Supplemental Table 3). The number of
cases of DIKD also peaked in the 6th–8th decade in all
pathological categories, except for in the cases involving
CTIL, in which it peaked in the 4th–5th decade (Fig. 4a, b,
Supplemental Fig. 2).
Baseline clinical and laboratory characteristics
of the DIKD patients
The patients’ urinary findings are shown in Table 3. In
dipstick tests, 104 cases (31.7 %) were classified as (-) or
(±), and 83 cases (25.3 %) were classified as C3?. Simi-
larly, 77 cases (32.5 %) and 58 cases (24.2 %) involved
patients that exhibited daily proteinuria values of\0.3 g/day
(n = 237) or urinary protein/creatinine ratios (UPCR) of
\0.3 g/gCr (during spot urine tests) (n = 240). In addition,
86 cases (36.3 %) and 128 cases (51.7 %) involved patients
that demonstrated daily proteinuria values of C0.3 g/day
and UPCR of C0.3 g/gCr (in spot urine tests), respectively
(Table 3). As for the results obtained in each pathological
category, in the ATIL and CTIL categories 30 cases
(32.6 %) and 35 cases (48.6 %), respectively, were classi-
fied as (-) or (±) during dipstick tests (Table 4).
As for hematuria, 195 cases (59.4 %) were found to be
(-) or (±) for occult blood in dipstick tests, and 235 cases
(70.6 %) were considered to be red blood cell (RBC)-neg-
ative or to have\5 RBC/high-powered field (hpf) in their
urinary sediments (Table 3). In addition, 52 cases (56.5 %)
of ATIL and 54 cases (77.0 %) of CTIL were classified as
(-) or (±) for hematuria in dipstick tests (Table 4).
The baseline clinical and laboratory findings of the cases
in each of the 3 major pathological categories are shown in
Table 4. As mentioned above, the patients with ATIL and
CTIL exhibited milder urinary abnormalities than those with
glomerular lesions. However, more marked changes in the
serum creatinine level and the eGFR were seen in the
patients with ATIL or CTIL (ATIL, CTIL, and glomerular
lesions: mean serum creatinine levels: 3.42, 2.34, and
1.12 mg/dl, respectively; mean eGFR: 24.2, 33.6, and
66.6 ml/min/1.73 m2, respectively; p\ 0.001). On the other
hand, the patients with glomerular lesions exhibited lower
serum albumin levels (2.82 ± 0.95 g/dl, p\ 0.001), higher
serum cholesterol levels (274.4 ± 122 mg/dl, p\ 0.001),
and nephrotic range proteinuria (daily proteinuria:
3.11 ± 3.28 g; UPCR: 5.48 ± 5.69 g/gCr, p\ 0.001).
Table 1 Clinical diagnoses of the cases of drug-induced kidney
disease in the J-RBR (2007–2015)
Clinical diagnosis Cases %
DIKDa 150 45.7
Chronic nephritic syndrome ? DIKDa 46 14.0
Nephrotic syndrome ? DIKDa 45 13.7
RPGNb ? DIKDa 29 8.8
Nephrotic syndrome 17 5.2
Acute nephritic syndrome ? DIKDa 11 3.4
Acute kidney injury 5 1.5
Chronic nephritic syndrome 5 1.5
Recurrent hematuria ? DIKDa 4 1.2
Chronic nephritic syndrome ? others 4 1.2
Others 3 0.9
Nephrotic syndrome ? others 2 0.6
Nephrotic syndrome ? collagen disease/vasculitis 2 0.6
HUS/TTPc 1 0.3
Acute nephritic syndrome ? acute kidney injury 1 0.3
Acute kidney injury ? DIKDa 1 0.3
RPGNb 1 0.3
Collagen disease/vasculitis 1 0.3
Total 328 100
Based on their clinical symptoms, 136 patients (41.5 %) were given a
secondary diagnosis of DIKD, and a total of 286 patients (87.2 %)
were diagnosed with DIKD
J-RBR, Japan Renal Biopsy Registry; aDIKD, drug-induced kidney
disease; bRPGN, rapidly progressive glomerulonephritis; cHUS/TTP,
hemolytic uremic syndrome/thrombotic thrombocytopenic purpura
Table 2 Pathological categories of the cases of drug-induced kidney
disease in the J-RBR (2007–2015)
Pathological diagnosis Cases %
Acute kidney injuries 87 26.5
Acute tubulointerstitial nephritis 76 23.2
Acute tubular necrosis 11 3.4
Chronic tubulointerstitial lesions 72 22.0
Glomerular disorders 105 32.0
Membranous nephropathy 63 19.2
Minor glomerular abnormalities 14 4.3
Mesangial proliferative glomerulonephritis 12 3.7
Crescentic glomerulonephritis 8 2.4
Membranoproliferative glomerulonephritis Type I
or III
3 0.9
Focal segmental glomerulosclerosis 3 0.9
Endocapillary proliferative glomerulonephritis 2 0.6
Sclerotic lesions 18 5.5
Nephrosclerosis 14 4.3
Sclerosing glomerulonephritis 4 1.2
Others 45 13.7
Transplanted kidney 1 0.3
Total 328 100
J-RBR, Japan Renal Biopsy Registry
Clin Exp Nephrol (2016) 20:720–730 723
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The CGA risk classification (heat map) in each
pathological category of DIKD
The CGA classification results for each pathological cate-
gory are shown in Fig. 5 and Supplemental Tables 4 and 5.
With regard to the G and A stages of the DIKD patients,
stages G4 and A3 were the most common from 2007 and
2015. Furthermore, 123 cases (39.7 %) were considered to
involve advanced G stages (G4 or 5), and 175 cases
(58.5 %) were classified as stage A3.
The degree of proteinuria detected in the patients’ 24-h
urine or spot urine samples increased with the G stage,
even among the cases involving AKII and CTIL. Accord-
ing to the CGA risk classification, high-risk (red zone)
cases accounted for 56.1 % of all cases of DIKD and 75.9,
64.9, and 33.3 % of cases involving ATIL, CTIL, and
glomerular lesions, respectively (Fig. 5a–d).
The causative drugs in 102 cases
The causative drugs were identified in 102 cases. Of these,
bucillamine was the causative drug in 38 cases of MN;
calcineurin inhibitors (CNI), such as cyclosporine or
tacrolimus, were found to be the causative drug in 27 cases
of CTIL or sclerotic lesions; and anticancer drugs were
demonstrated to be the causative drugs in 17 cases (in-
cluding gemcitabine in 3 cases of thrombotic microan-
giopathy and anti-vascular endothelial growth factor
(VEGF) drugs in 3 cases with various pathologies). Anti-
neutrophil cytoplasmic antibody (ANCA)-related nephritis,
a representative glomerular lesion, was caused by propyl
thiouracil (PTU) in 3 cases (Table 5, Supplemental Fig. 3).
0
10
20
30
40
50
60
70
80
90
100
< 10 10 - 19 20 - 29 30 - 39 40 - 49 50 - 59 60 - 69 70 - 79 80+
0
10
20
30
40
50
60
< 10 10 - 19 20 - 29 30 - 39 40 - 49 50 - 59 60 - 69 70 - 79 80+
(A) (B)
Male
Female
Fig. 2 Number of cases of drug-induced kidney disease in the
J-RBR. a The number of cases of drug-induced kidney disease
increased with age, peaking in the 7th decade*. b The number of
cases peaked in the 6th–8th decade in both genders, and the males
exhibited an especially marked peak in the 7th decade (*data for each
decade are shown in Supplemental Table 2)
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Fig. 3 The frequency of drug-induced kidney disease among renal
biopsied cases according to age. The frequency of drug-induced
kidney disease increased with age and peaked in the 7th decade*. The
frequency of drug-induced kidney disease was elderly 3 times higher
in the 7th decade than in the 2nd decade (1.86 vs. 0.62 %) (*data for
each decade are shown in Supplemental Table 3)
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Discussion and comments
J-RBR/J-KDR and DIKD
In Japan, renal biopsies have been recorded in the J-RBR
since 2007, and clinically diagnosed cases of kidney dis-
ease in which renal biopsies were not performed have been
registered in the J-KDR since 2009 [1, 2]. More than 18 %
of cases of DIKD were registered in the J-RBR in 2009 and
2010 [2]; however, only 7 out of 231 cases (3.0 %) of the
condition were registered in the J-KDR from 2007 to 2013
(data not shown); thus, the data from the J-RBR are
described in this report. It was speculated that the J-RBR
contains data about 20–25 % of the renal biopsies per-
formed in Japan. Thus, reports based on the J-RBR are
considered to provide representative data of renal biopsied
cases for Japan.
Clinical presentation of DIKD
Among drug-induced kidney injuries, DIKD accounts for
19–26 % of cases of AKI involving hospitalized patients
[8]. However, DIKD is often unrecognized because there
are no standard clinical definitions for the condition. Our
data showed that 12.8 % of DIKD cases were diagnosed
based on their pathological findings. Recently, the Inter-
national Serious Adverse Event Consortium [13] and the
working group of Mehta et al. [9] initiated a phenotype
standardization project to develop consensus definitions for
drug-induced organ toxicities, including DIKD, based on
patients’ clinical symptoms. As a result, Mehta et al. pro-
posed 4 phenotypes of DIKD: AKI, glomerular disorders,
tubular dysfunction, and nephrolithiasis, and suggested that
they are useful for evaluating drug toxicities across various
settings [9]. Previous reports (published in 2007–2009)
from the study group of the Japanese Ministry of Welfare
and Labor showed that among the hospitals at which 47
representative nephrologists worked (the hospitals were
located throughout Japan) DIKD accounted for 0.935 % of
all admissions [14]. The major causative drugs responsible
for the patients’ renal injuries were non-steroidal anti-in-
flammatory drugs (NSAID) in 25.1 % of cases, anticancer
drugs in 18.0 % of cases, antibiotics in 17.5 % of cases,
and radiocontrast agents in 5.7 % of cases. In these cases,
54.6 % of the renal injuries were direct renal injuries.
Moreover, 36.5 % of the patients did not recover. In the
current study, we dealt more severe and complex cases of
DIKD, in which the clinicians decided to perform renal
biopsies to obtain more accurate pathological diagnoses.
Therefore, it is not surprising that there were discrepancies
in the patients’ background data between our study popu-
lation and those of previous studies in which DIKD was
diagnosed based on the patients’ clinical symptoms. Thus,
we need to obtain up-to-date information about non-renal
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Fig. 4 The frequency of each pathological category of drug-induced
kidney disease according to age. a Total number of cases in each
pathological category, b the frequency of each pathological category
in each decade. The number of cases peaked in the 6th–8th decade in
all pathological categories, except for the number of cases involving
chronic tubulointerstitial lesions, which peaked in the 4th–5th decade
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biopsied DIKD patients based on standardized clinical
criteria in future.
Pathology of DIKD and newer drugs
Previous studies in which DIKD was diagnosed based on
the patients’ clinical symptoms obtained quite different
findings regarding the frequencies of each clinical category
and causative drug among DIKD patients than the present
study. However, studies in which DIKD was diagnosed
based on the patients’ pathological findings reported sim-
ilar pathological data regarding the patients’ categories.
Since the 1980s, it has been recognized that drug-induced
acute interstitial nephritis associated with methicillin or
other penicillins, diuretics, or NSAID commonly presents
as acute renal failure [15]. In addition, tubulointerstitial
lesions such as acute tubular necrosis can be caused by
directly tubulo-toxic drugs (e.g., cisplatin, gentamicin,
etc.), which induce minimal glomerular histological chan-
ges in the human kidney. In toxicological screening pro-
grams for nephrotoxic substances, it was suggested that
some types of drug-induced renal injuries are mediated by
immune mechanisms; i.e., immune complex glomerular
disease and nil disease (a minor glomerular abnormality)
[16]. In the past decade, we have identified other
glomerular lesions such as collapsing focal segmental
glomerulosclerosis, which can be caused by pamidronate
[17] and other drugs. Finally, a number of newer therapies
such as anti-VEGF therapy have emerged as causative
agents of renal toxicity, which produce a variety of
pathological changes in the kidney [18, 19]. Some drugs
can cause irreversible changes and even end-stage renal
disease [20, 21]. The present study included some cases of
DIKD involving these new drugs, such as gemcitabine,
PTU, and anti-VEGF drugs, and their associated patho-
logical findings. In addition, it was demonstrated that
bucillamine is a major cause of DIKD-associated
glomerular lesions in Japan. Cases of MN involving a
different IgG subclass from idiopathic MN have been
described in the literature, and such renal changes are
considered to be characteristic bucillamine-induced lesions
[22, 23] (Supplemental Table 6). However, the precise
mechanisms responsible for bucillamine-induced MN
remain unclear.
Aging and DIKD
Our analysis of the J-RBR revealed that in Japan DIKD
mainly affects the elderly. There are several possible rea-
sons for this: (1) the elderly are exposed to drugs more
frequently than younger individuals, (2) the elderly are
administered inappropriate doses of nephrotoxic drugs that
have not been adjusted for age-related renal and systemic
changes, (3) the use of serum Cr levels for diagnostic
purposes might be of limited use in the elderly, and (4)
there is a lower chance of renal recovery in older patients.
It is well known that the risk of developing AKI is sig-
nificantly increased in the elderly for various reasons, e.g.,
they are at greater risk of drug toxicities, such as contrast
medium-induced nephropathy [24].
As concern to ATIL in the elderly, Muriithi et al.
reported recently that drug-induced acute interstitial
nephritis (AIN) (87 vs. 64 %), especially proton pump
inhibitor (PPI)-induced AIN (18 vs. 6 %), was observed
significantly more in the elderly compared with younger
patients. Moreover, the elderly had higher prevalence of
baseline CKD, higher peak creatinine, and more need for
dialysis. Thus, the vast majority of AIN cases in the elderly
are due to drugs, primarily owing to PPI and antibiotics in
the United State [25].
Table 3 Urinalysis results of all cases of drug-induced kidney
disease
Urinary protein (dipstick test) Cases %
(-) 67 20.4
(±) 37 11.3
1? 75 22.9
2? 66 20.1
3? 55 16.8
4? 28 8.5
Total 328 100.0
Daily proteinuria levels and urinary protein levels according to spot
urine tests
g/day Cases % g/gCr Cases %
\0.30 77 32.5 \0.30 58 24.2
0.30–0.49 22 9.3 0.30–0.49 19 7.9
0.50–0.99 52 21.9 0.50–0.99 39 16.3
1.00–3.49 45 19.0 1.00–3.49 64 26.7
3.50? 41 17.3 3.50? 60 25.0
Total 237 100.0 Total 240 100.0
Hematuria (occult blood grade and red blood cell grade of urinary
sediment)
OB Cases % /hpf Cases %
(-) 144 43.9 (-) 91 27.7
(±) 51 15.5 \5 144 43.9
1? 41 12.5 5–10 28 8.5
2? 46 14.0 \10–30 26 7.9
3? 46 14.0 Many 39 11.9
Total 328 100.0 Total 328 100.0
OB, occult blood levels according to the dipstick test; hpf, high-
powered field
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Moreover, the frequencies of nephrotic syndrome-re-
lated glomerular diseases caused by immune complex
diseases, such as idiopathic MN and rapidly progressive
glomerulonephritis caused by ANCA-positive vasculitis
are increasing in Japan [4]. Aging might affect the immune
responses of the elderly. Thus, the elderly might be more
Table 4 Demographic characteristics of the patients with the 3 major pathological subtypes of drug-induced kidney disease
Category ATIL (92 cases) CTIL (72 cases) Glomerular lesions (106 cases) p value*
Mean SD Mean SD Mean SD
Age 56.9 18.49 52.9 18.59 55.79 19.6 0.346
Height (cm) 159.0 11.2 159.6 11.4 156.1 12.3 0.020
Weight (kg) 57.4 14.4 55.0 12.1 55.6 12.5 0.176
BMI 22.5 4.4 21.5 3.8 22.6 3.7 0.390
Systolic BP (mmHg) 126.9 22.5 121.5 17.5 126.3 19.3 0.314
Diastolic BP (mmHg) 73.8 14.4 73.2 14.0 75.8 11.9 0.576
Mean BP (mmHg) 91.5 16.0 89.3 14.0 92.6 13.3 0.455
Daily proteinuria (g) 0.73 1.00 0.82 2.30 3.11 3.28 \0.001
uPCR (g/gCr) 2.12 7.82 1.20 2.70 5.48 5.69 \0.001
Urinary protein levels\1? 30 (32.6 %) 35 (48.6 %) 18 (13.0 %) ND**
Urinary OB levels\1? 52 (56.5 %) 54 (75.0 %) 49 (46.2 %) ND**
Serum Cr (mg/dl) 3.42 2.72 2.34 2.24 1.12 1.13 \0.001
eGFR (ml/min/1.73 m2) 24.2 18.7 33.6 20.3 66.6 30.7 \0.001
Serum TP (g/dl) 6.90 1.07 7.10 0.82 5.94 1.12 \0.001
Serum Alb (g/dl) 3.35 0.72 3.96 0.58 2.82 0.95 \0.001
Serum TC (mg/dl) 177.1 46.0 187.5 43.6 274.4 122.0 \0.001
HbA1c (NGSP) (%) 6.14 0.80 5.93 1.27 5.91 0.78 0.017
ATIL, acute tubulointerstitial lesions; CTIL, chronic tubulointerstitial lesions; BP, blood pressure; OB, occult blood level according to the
dipstick test; uPCR, urinary protein to creatinine ratio; Cr, creatinine; eGFR, estimated glomerular filtration rate; TP, total protein; Alb, albumin;
TC, total cholesterol; HbA1c, glycated hemoglobin
* p values were calculated using ANOVA or the Kruskal–Wallis test; ** ND not determined
Stage A1 A2 A3 Subtotal
G1 6 2 21 29 10.2%
G2 8 2 32 42 14.7%
G3a 21 4 21 46 16.1%
G3b 29 3 22 54 18.9%
G4 16 5 39 60 21.1%
G5 12 7 35 54 18.9%
Subtotal
92 23 170 285 160
32.3% 8.1% 59.6% High risk 56.1%
Stage A1 A2 A3 Subtotal
G1 0 0 1 1 1.3%
G2 1 1 1 3 3.8%
G3a 5 2 0 7 8.9%
G3b 8 2 2 12 15.2%
G4 3 3 20 26 32.9%
G5 6 3 21 30 38.0%
Subtotal
23 11 45 79 60
29.1% 13.9% 57.0% High risk 75.9%
(A) Total cases (B) Acute tubulo-interstitial lesions
(C) Chronic tubulo-interstitial lesions (D) Glomerular lesions
Stage A1 A2 A3 Subtotal
G1 1 0 0 1 1.8%
G2 3 0 0 3 5.3%
G3a 5 1 2 8 14.0%
G3b 10 0 5 15 26.3%
G4 9 1 7 17 29.8%
G5 3 3 7 13 22.8%
Subtotal
31 5 21 57 37
54.4% 8.8% 36.8% High risk 64.9%
Stage A1 A2 A3 Subtotal
G1 5 2 16 23 23.2%
G2 2 1 31 34 34.3%
G3a 2 1 14 17 17.2%
G3b 6 1 7 14 14.1%
G4 0 0 5 5 5.1%
G5 1 0 5 6 6.1%
Subtotal
16 5 78 99 33
16.2% 5.1% 78.8% High risk 33.3%
Fig. 5 The CGA risk
classification of DIKD.
According to the CGA risk
classification, high-risk (red
zone) cases accounted for
56.1 % of all cases (a), and
75.9 % (b), 64.9 % (c), and
33.3 % (d) of those involving
acute tubulointerstitial lesions,
chronic tubulointerstitial
lesions, and glomerular injuries,
respectively (color
figure online)
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sensitive to drugs, e.g., they might be more susceptible to
drug-induced nephrotoxicity or exhibit hypersensitive
immune responses to drugs.
Limitations of this study
1. We cannot exclude the possibility that the J-RBR is
subject to sampling bias; however, the J-RBR repre-
sents the largest renal biopsy series of elderly (aged
over 65 years) and very elderly (over 75 years old)
patients in the world [4]. Thus, it is likely to be rea-
sonably representative of the nationwide situation of
renal biopsied cases in Japan.
2. We could not examine the outcomes of the DIKD
patients in this study. Further studies of the clinical
outcomes of DIKD will be necessary.
3. There are no standard definitions for drug-induced
nephrotoxicity based on patients’ clinical symptoms.
We need to develop clinical strategies for diagnosing
and managing DIKD.
Conclusion
Our analysis of the J-RBR revealed that DIKD mainly
affects elderly people in Japan. In addition, approximately
half of the renal biopsied cases involved ATIL or CTIL,
and roughly one-third involved glomerular lesions, mainly
MN and clinical nephrotic syndrome. In future studies, we
need to examine the outcomes of DIKD and develop
clinical strategies for managing the condition.
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ATIL, acute tubulointerstitial lesions; CTIL, chronic tubulointerstitial lesions; MN, membranous
nephropathy; DMARD, disease modified anti-rheumatic drugs; CNI, calcineurin inhibitor; TMA, throm-
botic microangiopathy; VEGF, vascular endothelial growth factor; CrGN, crescentic glomerulonephritis;
NS, nephrosclerosis; NSAID, non-steroidal anti-inflammatory drugs; PTU, propyl thiouracil; ANCA, anti-
neutrophil cytoplasmic antibody
a All cases were registered in the J-RBR after July 2012
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